Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
NCT04389580Phase 2Unknown
- Sponsor
- Kafrelsheikh University
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of isotretinoin and tamoxifen in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Kafrelsheikh University. Primary endpoint: Lung injury score at 7 days. Status: unknown.
02
Drugs
isotretinointamoxifen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04389580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04389580.